Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Adenocarcinoma: early-phase trial registry
27 of 44 indexed Esophageal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #330 of 28,707 conditions by registered trial count.
44 US clinical trials · 27 currently recruiting · #330 of 28,707 conditions by registered trial count
Esophageal Adenocarcinoma: 44 US clinical trials tracked, 27 recruiting.
Esophageal Adenocarcinoma is the subject of 44 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 3 of these trials.
Enrollment posture brief
Registry condition esophageal-adenocarcinoma
OPEN 27 | RECR 61% | LATE 2 | EARLY 28 | RANK #330 | SPON 3
Volume-matched condition peers
Nearest open-share peer: ACL Injury (62% recruiting · 13 trials)
Esophageal Adenocarcinoma lists 27 open slots (61% of 44 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Esophageal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Esophageal Adenocarcinoma is recruiting above its size-band peers.
27 of 44 indexed trials (61.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Esophageal Adenocarcinoma trials is spread across many organizations.
Mayo Clinic accounts for 3 of 44 trials (6.8%). 33 distinct sponsors appear on at least one study for this condition label.
-
Typical Esophageal Adenocarcinoma enrolment sits around 72 participants.
Median target enrolment is 72 among the 44 trials that report a genuine target (sentinel values excluded). 25 of those (56.8%) plan for fewer than 100 participants.
-
Esophageal Adenocarcinoma research is mostly interventional.
38 interventional and 6 observational studies make up this index (86.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
44 total, page 1 of 1
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
Midwest Biomedical Research Foundation
NCT00574327
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
University of Colorado, Denver
NCT05530343
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Mayo Clinic
NCT03961945
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
Case Comprehensive Cancer Center
NCT06687603
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
NCT06324357
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
University of Colorado, Denver
NCT05753748
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
Mayo Clinic
NCT06071845
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AstraZeneca
NCT06005493
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
AbbVie
NCT06628310
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT07432295
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium
NCT07284186
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune
NCT07021066
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Anwaar Saeed
NCT03539822
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
Roswell Park Cancer Institute
NCT04682158
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co.
NCT06266299
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
VA Office of Research and Development
NCT05563766
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT04114136
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Yale University
NCT07282912
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
University of Wisconsin, Madison
NCT04150640
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
NCT02366819
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
NCT04939051
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Weill Medical College of Cornell University
NCT06340711
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
Denver Health and Hospital Authority
NCT06532734
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06623396
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Memorial Sloan Kettering Cancer Center
NCT02962063
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology
NCT05945823
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
Weill Medical College of Cornell University
NCT02998268
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT04430738
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
National Cancer Institute (NCI)
NCT02521285
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
NCT04929392
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
NCT05480384
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
University of North Carolina, Chapel Hill
NCT02075905
Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
Memorial Sloan Kettering Cancer Center
NCT01970306
The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)
Columbia University
NCT05524844
Esophageal Cytology With FISH in Detecting Esophageal Cancer
OHSU Knight Cancer Institute
NCT02100189
Confocal Endomicroscopy for Barrett's Esophagus
Johns Hopkins University
NCT00487695
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma
University of Oklahoma
NCT03526328
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
Columbia University
NCT02513784
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
Seagen
NCT04499924
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
OHSU Knight Cancer Institute
NCT02890979
Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue
Mayo Clinic
NCT00909350
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 17 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Esophageal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Esophageal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Esophageal Adenocarcinoma page
44 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Esophageal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Esophageal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esophageal Adenocarcinoma condition card totals 44 registered trials; most-linked intervention Oxaliplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.